20th International Congress » Parkinson's disease: Pathophysiology

Date: Tuesday, June 21, 2016

Time: 12:30pm-2:00pm

Location: Exhibit Hall located in Hall B, Level 2

Session Type: Poster Session

Meeting: 20th International Congress

12:30pm-2:00pm: α-synuclein CSF levels correlate with urinary dysfunction in early de novo Parkinson’s disease patients

G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

12:30pm-2:00pm: α-synuclein in peripheral organs decreases in Lewy body disease complicated by Alzheimer’s disease

H. Sumikura, J. Fujigasaki, Y. Nakano, A. Uchino, Y. Saito, H. Mochizuki, S. Murayama (Tokyo, Japan)

12:30pm-2:00pm: A comprehensive characterisation of the salivary proteome of patients with Parkinson’s disease

J.M. Masters, A.J. Noyce, S. Lynham, T.T. Warner, G. Giovannoni, G.B. Proctor (Herts, United Kingdom)

12:30pm-2:00pm: A novel C. elegans model for identification of small molecules that target alpha-synuclein-mediated toxicity

L.V. Kalia, K. Menezes, Y. Zhang, S. Ishikura, N. Tran, H. Chau, A.M. Lozano, S.K. Kalia, J.G. Culotti, S. Suo, W.S. Ryu (Toronto, ON, Canada)

12:30pm-2:00pm: A novel single molecule imaging approach to detect individual protein oligomers in CSF from patients with Parkinson’s disease (PD)

S. Gandhi, M.H. Horrocks, S.F. Lee, N.W. Wood, D. Klenerman (London, United Kingdom)

12:30pm-2:00pm: A whole brain anatomical network model and its application in PD research

X. Lei, T. Chen, X. Hu, B. Zhang (Kunming, People's Republic of China)

12:30pm-2:00pm: Alpha synuclein and crystallin expression in human lens in Parkinson’s disease

S.A. Schneider, E. Richert, G. Kuhlenbäumer, B. Nölle, K.P. Bhatia, G. Deuschl, J. Roider, A. Klettner (München, Germany)

12:30pm-2:00pm: Alpha-synuclein – super-resolution microscopy reveals potential new role of alpha-synuclein at the pre-synapse

J. Lautenschlaeger, F. Stroehl, A. Stephens, C.F. Kaminski, G.S. Kaminski Schierle (Cambridge, United Kingdom)

12:30pm-2:00pm: Alpha-synuclein gene variants may predict neurostimulation outcome

D. Weiss, S. Herrmann, L. Wang, C. Schulte, K. Brockmann, C. Plewnia, T. Gasser, M. Sharma, A. Gharabaghi, R. Krüger (Tübingen, Germany)

12:30pm-2:00pm: Alpha-synuclein in gastric and colonic mucosa in Parkinson’s disease: Limited role as a biomarker

S.J. Chung, J. Kim, H.J. Lee, H.S. Ryu, K.W. Jung, M.J. Kim, M.J. Kim, S.M. Hong, S.J. Myung (Seoul, Korea)

12:30pm-2:00pm: Alterations in 14-3-3 protein phosphorylation as a biomarker for neurodegeneration

T. Yacoubian, X. Chi, G. Cutter, M. McFerrin (Birmingham, AL, USA)

12:30pm-2:00pm: An exuberant cortical γb influences the unmasking and intensity of dyskinesia in 6-OHDA-treated freely-moving rats

S. Galati, V. D'Angelo, A. Salvadè, A. Kaelin, A. Stefani (Lugano, Switzerland)

12:30pm-2:00pm: Analysis of relationships between spinal deformity and walking ability in Parkinson’s disease patients

Y. Nakamura, Y. Machida, T. Hanawa, M. Kanai, K. Tajima, S. Asano (Satte, Japan)

12:30pm-2:00pm: Apathy phenotype in Parkinson’s disease: Motor and non-motor features

S. Varanese, A. Di Rocco, M.F. Ghilardi, N. Modugno, R. Gilbert-Wolf, B. Perfetti (Pozzilli, Italy)

12:30pm-2:00pm: APL-130277 is a sublingual film being studied in phase 3 trials to rapidly turn patients ON from OFF episodes by delivering apomorphine via the oral mucosa

H. Shill, E.J. Pappert, A. Agro, B. Dzyngel, T. Bilbault, R. Hauser, S. Isaacson (Phoenix, AZ, USA)

12:30pm-2:00pm: Association of Parkinson’s disease severity and cortical and subcortical cognitive markers

H. Duran-Meza, A.D. Santana-Vargas, J.D. Ramirez-Diossa, G.H. Terrazas Gonzalez, G. Millan-Rosas, U. Jimenez-Correa, M. Lopez-Ruiz (Mexico City, Mexico)

12:30pm-2:00pm: Associations between cerebrospinal fluid proteins and cytokines in Parkinson’s disease

R. Wijeyekoon, S. Moore, K. Farrell, D. Breen, R. Barker, C.H. Williams-Gray (Cambridge, United Kingdom)

12:30pm-2:00pm: Astroglia exert a neuro-protective role in Parkinson’s disease by reducing oxygen stress through dopamine-induced activation of the pentose-phosphate pathway

K. Mashima, S. Takahashi, T. Iizumi, T. Abe, N. Suzuki (Tokyo, Japan)

12:30pm-2:00pm: Bcr-Abl tyrosine-kinase inhibitors (B-ATKI) and Parkinson’s disease (PD)

E.A. Shamim, S.F. Baker, F.F. Liu, K.K. Mane, J.G. Layug, S. Vupputuri, C.C. DiStasio, S.M. Khandhar, C. Neff, S. Van Den Eeden, C. Lungu, R. Cooley, H.S. Martel, C. Chen, J. Dorman, M.A. Sinkiewicz, J. Klingman (Largo, MD, USA)

12:30pm-2:00pm: Bi-hemispheric phase synchronization in patients with Parkinson’s disease during stance, gait and upper limb motor tasks

M. Plotnik, Y. Miron, S. Hassin-Baer, O.S. Cohen, S. Kimel-Naor, I. Blatt, R. Inzelberg, J.W. Kantelhardt (Tel Hashomer, Israel)

12:30pm-2:00pm: Brain metabolic profile changes reflect subtle pathological alterations in different murine models of Parkinson’s disease

E. Glaab, F. Giesert, C. Jaeger, P. Dirscherl, A. Zimprich, A. Ulusoy, D.A. Di Monte, P. Garcia, R. Balling, W. Wurst, D. Truembach, M. Buttini, D. Vogt-Weisenhorn (Esch-Alzette, Luxembourg)

12:30pm-2:00pm: Carrier mediated delivery system bearing dopamine for effective management of parkinsonism

V. Bhargava, S. Bhargava (Kanpur, India)

12:30pm-2:00pm: Cell-surface expression of dopamine transporter facilitates the uptake of α-synuclein

J. Kobayashi, T. Hasegawa, S. Yoshida, N. Sugeno, R. Oshima, A. Kikuchi, A. Takeda, M. Aoki (Sendai, Japan)

12:30pm-2:00pm: Cellular senescence induced by paraquat drives neuropathology associated with Parkinson’s disease

S.J. Chinta, G. Woods, M. Demaria, J. Campisi, J.K. Andersen (Novato, CA, USA)

12:30pm-2:00pm: Cerebellar atrophy in Parkinson’s disease and its implication for network connectivity

J.M. Shine, C. O'Callaghan, M. Hornberger, G.M. Halliday, S.J.G. Lewis (Palo Alto, CA, USA)

12:30pm-2:00pm: Changes in serum amino acid levels with progression of Parkinson’s disease

M. Figura, K. Kusmierska, E. Bucior, S. Szlufik, D. Koziorowski, Z. Jamrozik, A. Friedman, P. Janik (Warsaw, Poland)

12:30pm-2:00pm: Characteristics of the interaction between different toxic aggregated species of alpha-synuclein and cell membrane

A.T. Marvian, D. Morshedi, F. Aliakbari, H. Ghapani, M. Nasuti (Tehran, Islamic Republic of Iran)

12:30pm-2:00pm: Characterization of striatal TH-immunoreactive cells in chronic and acute L-DOPA treatment in a mice model of Parkinson´s disease

G. Gomez, M. Bordone, S.I. Sanz-Blasco, M.A. Bernardi, J.E. Ferrario, I.R.E. Taravini, M.G. Murer, O.S. Gershanik (Buenos Aires, Argentina)

12:30pm-2:00pm: Chronic cerebral hypoperfusion accelerates cognitive dysfunction and microvascular impairment in the MPTP mouse model of Parkinson’s disease

H. Tang, R. Zhu, L. Gao, K. Nie, S. Feng, Z. Duan, Y. Zhang, X. Zhao, L. Wang, J. Zhao, Z. Huang, Y. Zhang, L. Wang (Guangzhou, People's Republic of China)

12:30pm-2:00pm: Circadian dysfunction in Parkinson’s disease: Effects on impaired gait initiation and locomotion

L. Alibiglou, J. Stewart, G. Bachman, C. Cooper, L. Liu, S. Ancoli-Israel (Chicago, IL, USA)

12:30pm-2:00pm: Clinical aspects of postural instability in Parkinson’s disease

T.S. Lovtsova, A.F. Vasilenko (Chelyabinsk, Russia)

12:30pm-2:00pm: Clinical predictors of airway protective dysfunction in Parkinson’s disease

M.S. Troche, A.E. Brandimore, B. Schumann, M.S. Okun, K.W. Hegland (New York, NY, USA)

12:30pm-2:00pm: Cognitive and depressive behavior changes in aged mice with heterozygous deletions of VMAT2 or of DAT

K. Ma, J. Huang, L. Liu, H. Jiang, X. Xu, C. Han, Y. Shen, Y. Xia, S. Guo, L. Wang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

12:30pm-2:00pm: Colonic microbiome in Korean patients with Parkinson’s disease

D. Lee, Y.N. Kwon, T.B. Ahn (Seoul, Korea)

12:30pm-2:00pm: Constipation in early de novo Parkinson’s disease: Prevalence and correlates with clinical features, imaging and non-imaging biomarkers

G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

12:30pm-2:00pm: Cortical impairment as marker of dementia risk in probable REM sleep behavior disorder in Parkinson’s disease

A.D. Santana-Vargas, H. Duran-Meza, J.D. Ramirez-Diossa, G.H. Terrazas Gonzalez, M. Lopez-Ruiz, G. Millan-Rosas, U. Jimenez-Correa (Mexico City, Mexico)

12:30pm-2:00pm: Cortical role in the freezing of gait in Parkinson’s disease

M. Mihara, H. Otomune, H. Fujimoto, K. Konaka, Y. Watanabe, H. Mochizuki (Suita, Japan)

12:30pm-2:00pm: Counteracting PINK1/parkin deficiency by activating alternative mitophagic pathway: a potential therapeutic intervention for Parkinson’s disease

B. Koentjoro, J.S. Park, C.M. Sue (Sydney, Australia)

12:30pm-2:00pm: Cyclic glycine-proline increased in the cerebrospinal fluid of Parkinson’s patients after supplementation of blackcurrant anthocyanins: Potential biomarker for treatment

J. Guan, Y. Alamri, D. Fan, M. MacAskill, T. Anderson (Auckland, New Zealand)

12:30pm-2:00pm: Defective ubiquitinated mitochondria accumulation in aged Parkinsonian LRRK2^R1441G knockin mice

H.F. Liu, P.W.L. Ho, L.F. Li, G.C.T. Leung, C.S.C. Lam, M.H.W. Kung, D.B. Ramsden, S.L. Ho (Hong Kong, Hong Kong)

12:30pm-2:00pm: Detection of leucine-rich repeat kinase 2 in human biofluids

E. Mutez, W. Sibran, T. Comptdaer, P. Semaille, M. Drouyer, S. Bleuse, L. Defebvre, A. Destee, M.C. Chartier-Harlin, J.M. Taymans (Lille, France)

12:30pm-2:00pm: Difference of REM sleep behavior disorder between the onset of before and after Parkinson’s disease

T. Nomura, Y. Inoue, K. Nakashima (Yonago, Japan)

12:30pm-2:00pm: Differences between responders and non-responders of Istradefylline for the wearing off in Parkinson’s disease

A. Yoritaka, H. Mori, N. Hattori (Saitoma, Japan)

12:30pm-2:00pm: Differences of gut bacterial community relate to pathology progress in Parkinson’s disease

T. Minato, S. Hasegawa, Y. Fujisawa, H. Tsuji, T. Asahara, K. Nomoto, A. Okamoto, T. Maeda, K. Ohno, M. Hirayama (Nagoya, Japan)

12:30pm-2:00pm: Different patterns of spontaneous brain activity between tremor-dominant and postural instability/gait difficulty subtypes of Parkinson’s disease: A resting-state fMRI study

H. Chen, Z. Wang, J. Fang, L. Gao, T. Feng (Beijing, People's Republic of China)

12:30pm-2:00pm: Differential expression of cerebral dopamine neurotrophic factor (CDNF) in the hippocampus and in the striatum of LRRK-2 mutant rat model of Parkinson’s disease

J. Varghese, K. Terpstra, S. Chiu, R. Mishra, Y. Bureau (London, ON, Canada)

12:30pm-2:00pm: Differential vulnerability to α-synuclein pathology among neuronal subpopulations

E. Luna, D.M. Riddle, V.M.Y. Lee, K.C. Luk (Philadelphia, PA, USA)

12:30pm-2:00pm: Diffusion tensor imaging (DTI) within the primate caudate nucleus marks dopaminergic (DA) and serotonergic (5-HT) lesions

S. Thobois, E. Météreau, M. Beaudoin-Gobert, S. Duperrier, L. Tremblay, V. Sgambato-Faure (Bron, France)

12:30pm-2:00pm: Diffusion tensor imaging biomarkers of nigrostriatal neurodegeneration in early Parkinson’s disease

J.A. Pineda-Pardo, G. Foffani, J.A. Obeso (Madrid, Spain)

12:30pm-2:00pm: Discrimination of Parkinson’s disease participants from healthy controls using telephone-quality voice recordings

S. Arora, A. Tsanas (Oxford, United Kingdom)

12:30pm-2:00pm: Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease from OFF to fully ON

H. Shill, E.J. Pappert, A. Agro, B. Dzyngel, T. Bilbault, S. Isaacson, R. Hauser (Phoenix, AZ, USA)

12:30pm-2:00pm: Disruption of circadian rhythm function and anti-oxidation via SIRT1-BMAL1 pathway in 6-OHDA induced Parkinson’s disease model

Y. Wang, S. Li, C. Mao, Y. Yang, F. Wang, C.F. Liu (Suzhou, People's Republic of China)

12:30pm-2:00pm: DJ-1 regulates intracellular signaling in a highly cell type specific manner

F. Giesert, D.M. Vogt Weisenhorn, U. Hafen, A. Romanov, A. Kurz-Drexler, W. Wurst (Neuherberg, Germany)

12:30pm-2:00pm: Drp1 inhibition amelioratesα-synuclein-mediated neurodegeneration in rats

S. Bido, L. Arcuri, M. Helly, R. Fan, K. Tieu, E. Bezard (Bordeaux, France)

12:30pm-2:00pm: Dynamic and static posturographic analysis among fallers and non- faller Parkinson’s disease (PD) patients using Neurocom SMART EquiTest

A. Lieberman, C. Frames, A. Deep, M. McCauley, S. Shafer (Phoenix, AZ, USA)

12:30pm-2:00pm: Effect of intra-striatal 6-OHDA lesion on extra-striatal structures in the mouse

B. Becker, M. Demirbas, C. Beyer, S. Tan, M. Kipp (Aachen, Germany)

12:30pm-2:00pm: Effect of vibration on motor performance: A new intervention to improve bradykinesia in Parkinson’s disease?

A. Macerollo, C. Palmer, T. Foltynie, P. Korlipara, P. Limousin, M. Edwards, J. Kilner (London, United Kingdom)

12:30pm-2:00pm: Effects of Arachidonyl-2′-chloroethylamide (ACEA), a selective CB1 receptor agonist, in MPTP mouse model of Parkinson’s disease

M. Omidbeigi, S. Asaadi, A. Zali (Tehran, Islamic Republic of Iran)

12:30pm-2:00pm: Evaluation of regional changes in striatal DAT binding in a progressing Parkinson’s disease (PD) cohort: Lessons for imaging biomarker assessment in disease-modifying therapeutic trials

J.P. Seibyl, D. Jennings, K. Marek (New Haven, CT, USA)

12:30pm-2:00pm: Evaluation of the role of oxidative stress in Parkinson’s disease and Parkinson plus syndrome

R. Qadri, M.A. Faiq, M. Behari, V. Goyal, A.K. Mukhopadhyay (New Delhi, India)

12:30pm-2:00pm: Exosomes-injection to reproduce a mouse model of Parkinson’s disease: A preliminary report

C. Han, J. Huang, K. Ma, Y. Shen, L. Liu, G. Zhang, X. Xu, J. Li, H. Jiang, S. Guo, Y. Xia, L. Wang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

12:30pm-2:00pm: Exploring aging-VMAT2 gene-rotenone interactions in a cell model for Parkinson’s disease

H. Jiang, J. Li, C. Han, K. Ma, L. Liu, Y. Shen, L. Wang, S. Guo, Y. Xia, J. Huang, T. Wang (Wuhan, People's Republic of China)

12:30pm-2:00pm: F1 crossbreds of C57BL/6 and CD-1 mice demonstrate resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced nigral neurodegeneration

P.A. Alladi, D. Vidyadhara, H. Yarreiphang, T.R. Raju (Bengaluru, India)

12:30pm-2:00pm: Falls in Parkinson’s disease: Beware the short, slow steps

A. Lieberman, A. Deep, S. Shafer, T. Lockhart (Phoenix, AZ, USA)

12:30pm-2:00pm: Floor square size predicts step count of 360° turns in PD patients with freezing

U.M. Fietzek, L. Stuhlinger, A. Plate, A.O. Ceballos-Baumann, K. Bötzel (Munich, Germany)

12:30pm-2:00pm: Gait impairment is more than a motor symptom in Parkinson’s disease

H.F. Chan, D.K.W. Chau, T. Fung, Y.F. Cheung, W.C. Fong (Hong Kong, Hong Kong)

12:30pm-2:00pm: Gender-age features of autonomic heart rhythm disturbances in Parkinson’s disease patients

I. Solodovnikova (Odessa, Ukraine)

12:30pm-2:00pm: Gene expression analysis using the Parkinson’s disease map reveals early effects of alpha-synuclein on PD pathogenesis

S. Gebel, A. Ashrafi, P. Garcia, M. Ostaszewski, P. Gawron, L. Vallar, N. Nicot, T. Kaoma, R. Balling, E. Glaab, M. Buttini (Esch-sur-Alzette, Luxembourg)

12:30pm-2:00pm: Generation and characterization of midbrain organoids from iPSCs of familial Parkinson’s disease

E. Frattini, G. Monzio Compagnoni, S. Salani, P. Rinchetti, M. Nizzardo, M. Baccarin, N. Bresolin, G.P. Comi, S.P. Corti, A. Di Fonzo (Milan, Italy)

12:30pm-2:00pm: Generation of dopaminergic neurons for studying Parkinson’s disease using patient blood cells

D. Ma, W. Zhou, Y. Chao, Y. Zhao, E.K. Tan (Singapore, Singapore)

12:30pm-2:00pm: Glatiramir acetate (Copaxone) causes restoration of the striatal dopamine in a progressive MPTP mouse model of Parkinson’s disease

C.K. Meshul, M.J. Churchill (Portland, OR, USA)

12:30pm-2:00pm: Glucocerebrosidase activity in a cohort of PD patients

I. Trezzi, V. Melzi, G. Franco, L. Borellini, E. Monfrini, A. Bordoni, N. Bresolin, G.P. Comi, A. Di Fonzo (Milan, Italy)

12:30pm-2:00pm: Glutathione status in Parkinson’s disease

L.K. Mischley (Kenmore, WA, USA)

12:30pm-2:00pm: Heterozygous PINK1 p.G411S mutation increases risk for Parkinson’s disease (PD)

W. Springer, A. Puschmann, F.C. Fiesel, M. Ando, T.R. Caulfield, K. Ogaki, M.G. Heckman, R. Hudec, E.D. James, G. Opala, J. Siuda, M. Boczarska-Jedynak, A. Friedman, D. Koziorowski, J.O. Aasly, T. Lynch, G.D. Mellick, M. Mohan, P.A. Silburn, Y. Sanotsky, C. Vilariño-Güell, M.J. Farrer, T. Dawson, Z.K. Wszolek, O.A. Ross (Jacksonville, FL, USA)

12:30pm-2:00pm: Histone deacetylase 4 is regulated by microRNA 128 in SH-SY5Y cells of Parkinson’s disease

J. Li, N. Xiong, H. Jiang, L. Liu, C. Han, K. Ma, X. Xu, Y. Shen, Y. Xia, L. Wang, S. Guo, J. Huang, T. Wang (Wuhan, People's Republic of China)

12:30pm-2:00pm: Hyperin inhibits lipopolysaccharide-induced microglia activation through p38 and NFκB signaling

X. Zhang, Y.N. Wang, H.H. Fan, R. Yang, S.Y. Li, J.H. Zhu (Wenzhou, People's Republic of China)

12:30pm-2:00pm: Identifying freezing of gait and falls in Parkinson’s disease patients using a body-worn sensor

Y. Okuma, H. Mitoma, M. Yoneyama (Izunokuni, Japan)

12:30pm-2:00pm: IL-6 and motor symptoms in Parkinson’s disease

T. Torgan, T. Baidina, N. Demchuk, M. Danilova (Perm, Russia)

12:30pm-2:00pm: Impact of prolonged temporal discrimination threshold on finger movements of Parkinson’s disease

M.J. Lee, J.S. Son, J.H. Lee, S.J. Kim, C.H. Lyoo, M.S. Lee (Busan, Korea)

12:30pm-2:00pm: Impairments in trunk muscle function influence head and trunk stability during walking in Parkinson’s disease fallers

M.H. Cole, G.A. Naughton, P.A. Silburn (Virginia, Australia)

12:30pm-2:00pm: In idiopathic Parkinson’s disease: The effect of using L-dopa on peripheral nerves

M.E. Temir, F. Genç, Y. Biçer Gömceli, A. Yaman, A. Aybar, E. Karaçay (Antalya, Turkey)

12:30pm-2:00pm: Increased anti-MAG autoantibodies titers in Parkinson’s disease

E. Papuc, K. Rejdak (Lublin, Poland)

12:30pm-2:00pm: Increased cellular co-localization of tau fragment 1-368 and alpha-synuclein in two mouse model of Parkinson’s disease

K. Ma, S. Nie, G. Chen, C. Han, X. Guo, Y. Xu, X. Cao (Wuhan, People's Republic of China)

12:30pm-2:00pm: Increased energy expenditure in early Parkinson’s disease during exercise

T. Margaliot Kalifa, N. Ziv, H. Bergman, S. Nusair, D. Arkadir (Jerusalem, Israel)

12:30pm-2:00pm: Influence of levodopa on functional brain connectivity in Parkinson’s disease

S. Kobayashi, K. Asano, N. Matsuda, H. Kubo, M. Abe, Y. Ugawa (Fukushima-shi, Japan)

12:30pm-2:00pm: Integrity of the superior longitudinal fascicle and its relationship with anticipatory postural adjustments in people with Parkinson’s disease and freezing of gait

A.C. de Lima-Pardini, T.Q. Freitas, D.B. Coelho, C.C. Boffino, C. Souza, R. Brandt, E.R. Barbosa, L.A. Teixeira, E. Amaro Jr. (São Paulo, Brazil)

12:30pm-2:00pm: Intrastriatal injection of ionomycin profoundly changes motor response to L-DOPA and its underlying molecular mechanisms

C. Han, S. Nie, G. Chen, K. Ma, N. Xiong, Z. Zhang, Y. Xu, T. Wang, S.M. Papa, X. Cao (Wuhan, People's Republic of China)

12:30pm-2:00pm: Investigating the role of Parkin in mitigating oxidative stress

J.M. Tokarew, D. El Kodsi, J.T. Tomlinson, M.G. Schlossmacher (Ottawa, ON, Canada)

12:30pm-2:00pm: Involvement of peripheral immune system in the pathogenesis of Parkinson’s disease

Y.X. Chao, S.C. Wong, K.J. Puan, J.J.Y. Tai, O. Rötzschke, B. Lee, M. Poidinger, E.K. Tan (Singapore, Singapore)

12:30pm-2:00pm: Is levodopa-induced dyskinesia in Parkinson’s disease associated with increased blood brain barrier permeability and volumetric changes?

O. Segal, D. Last, D. Guez, Y. Mardor, G. Yahalom, O.S. Cohen, S. Benizri, C. Hoffman, S. Hassin-Baer (Ramat Gan, Israel)

12:30pm-2:00pm: Is the assessment of 5 meters of gait with body-worn-sensors enough to recognize Parkinsonian gait?

M.E. Micó Amigo, I. Kingma, A. Kunikoshi, R.V. Lummel, W. Maetzler, J.V. Dieën (Amsterdam, Netherlands)

12:30pm-2:00pm: Kinematic analysis of repetitive finger movements and the effects of selegiline and pramipexole in early Parkinson’s disease

G. Leodori, M. Bologna, P. Stirpe, G. Paparella, D. Belvisi, A. Fasano, G. Fabbrini, A. Berardelli (Rome, Italy)

12:30pm-2:00pm: LC3 deacetylation by SIRT1 is involved in neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson’s disease

Y. Wu, Y. Guo, S. Dong, X. Cui, Y. Feng, W. Zhao (Shanghai, People's Republic of China)

12:30pm-2:00pm: Lessons learned from the Nilotinib trial: Cardio-vascular conditions in parkinsonism

Y. Torres-Yaghi, A. Keys, V. Ellen, S. Ashot, M. Elizabeth, S. Justin, M. Charbel, P. Fernando (Washington, DC, USA)

12:30pm-2:00pm: Lewy body extracts from Parkinson’s disease brains as models for high-throughput screens of neurotoxicity and α-synuclein spreading from cell-to-cell

E. Bezard, F. Cavaliere, P. Kitchener, E.Y. Pioli, B. Dehay, M. Bourdenx, P. Ramos-Gonzalez, J. Obeso, C. Matute (Bordeaux, France)

12:30pm-2:00pm: Localization and functional study of synaptic vesicle protein synaptogyrin-3 (SYNGR3) on dopaminergic neuronal system

L.F. Li, P.W.L. Ho, H.F. Liu, Z.H.M. Tse, C.S.C. Lam, M.C.T. Leung, M.H.W. Kung, D.B. Ramsden, S.W.L. Ho (Hong Kong, People's Republic of China)

12:30pm-2:00pm: Long-duration response to levodopa in Parkinson’s disease is independent of disease duration: A prospective study on de novo patients in Ghana

R. Cilia, E. Cereda, M. Amboni, A. Akpalu, F.S. Sarfo, M. Cham, M. Fabbri, G. Pezzoli (Milan, Italy)

12:30pm-2:00pm: Longitudinal cerebrospinal fluid biomarkers in early Parkinson’s disease and healthy controls

B. Mollenhauer, C.J. Caspell-Garcia, C.S. Coffey, P. Taylor, L.M. Shaw, J.Q. Trojanowski, A. Singleton, M. Frasier, K. Marek, D.R. Galasko (Kassel, Germany)

12:30pm-2:00pm: Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson’s disease

S. Hall, Y. Surova, A. Öhrfelt, K. Blennow, H. Zetterberg, O. Hansson (Lund, Sweden)

12:30pm-2:00pm: Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype

I. Huertas Fernandez, S. Jesus, J.A. Lojo, F.J. Garcia Gomez, M. Caceres Redondo, J.M. Oropesa Ruiz, F. Carrillo, L. Vargas Gonzalez, J.F. Martin Rodriguez, P. Gomez Garre, D. Garcia Solis, P. Mir (Sevilla, Spain)

12:30pm-2:00pm: Lrrk2 alleles modify host response to microbial infections

B. Shutinoski, I. Harmsen, M. Hakimi, Y.Y. Zhou, S. Sad, J.J. Tomlinson, E.G. Brown, M.G. Schlossmacher, CLINT Investigators (Ottawa, ON, Canada)

12:30pm-2:00pm: Lymphocytes have a detrimental effect on motor behavior in the AAV1/2 A53T α-synuclein mouse model of Parkinson’s disease

A.A. Karikari, M. Gehmeyr, E. Ribechini, V. Maltese, J. Volkmann, J.M. Brotchie, J.B. Koprich, M.B. Lutz, C.W. Ip (Würzburg, Germany)

12:30pm-2:00pm: Micro-RNA in cerebrospinal fluid as a biomarker for early diagnosis, differential diagnosis and prognostic marker in Parkinson’s disease

A. Fischbach, A.E. Roser, F. Maass, M. Börger, M. Bähr, I. Zerr, A. Fischer, P. Lingor (Göttingen, Germany)

12:30pm-2:00pm: Microglia P2Y6 receptor is related to Parkinson’s disease and involved in the neuroinflammatory process

X. Yang, Y. Lou, X. Wang, G. Liu, Y. Qian, J. Ding, S. Chen, Q. Xiao (Shanghai, People's Republic of China)

12:30pm-2:00pm: Mild mitochondrial impairment promotes corticostriatal synaptic plasticity alterations in PINK1 heterozygous knockout mice

P. Imbriani, G. Martella, G. Madeo, M. Maltese, V. Vanni, E. Ferraro, E.M. Valente, T. Schirinzi, L. Bonanni, J. Shen, N.B. Mercuri, P. Bonsi, A. Pisani (Rome, Italy)

12:30pm-2:00pm: Minimum MDS-UPDRS part III change needed to convert a Parkinson’s disease patient from the OFF to full ON state with apomorphine sublingual film (APL-130277)

H. Shill, A. Agro, E.J. Pappert, B. Dzyngel, T. Bilbault, S. Isaacson, R. Hauser (Phoenix, AZ, USA)

12:30pm-2:00pm: Mitochondrial dysfunction in skin fibroblasts from single heterozygous ATP13A2 (PARK9) mutation carriers

J.S. Park, C. Klein, C.M. Sue (St. Leonards, Australia)

12:30pm-2:00pm: Mitochondrial Hsp90 inhibitor G-TTP triggers PINK1/parkin-dependent mitochondrial quality control

F.C. Fiesel, J.D. Elle, H.R. Anneliese, H. Roman, S. Wolfdieter (Jacksonville, FL, USA)

12:30pm-2:00pm: Mitochondrial response precedes intracellular accumulation of α-synuclein in Parkinson’s disease

I. Milenkovic, E. Dassler, M. Weber, G.G. Kovacs (Vienna, Austria)

12:30pm-2:00pm: Mitochondrial-nuclear interplay in single respiratory chain-deficient Parkinson’s disease neurons

A. Grünewald, K.A. Rygiel, P.D. Hepplewhite, C.M. Morris, M. Picard, D.M. Turnbull (Belvaux, Luxembourg)

12:30pm-2:00pm: Modulating neuronal activity in dopaminergic neurons to promote their survival

M.A. Bernardi, N. Baffa-Trasci, O. Gershanik, M.E. Avale, J.E. Ferrario (Caba, Argentina)

12:30pm-2:00pm: Modulation of microglia function in the prion-like spreading of α-synuclein in the murine brain

W.M. Wemheuer, P. Garcia, E. Konica, A. Masuch, S. Brioschi, K. Biber, A. Weihofen, H. Kollmus, K. Schughart, D. Coowar, R. Balling, M. Buttini (Esch-sur-Alzette, Luxembourg)

12:30pm-2:00pm: Molecular landscape of Parkinson’s disease reveals a key role for lipids and lipoproteins

C.J.H.M. Klemann, G.J.M. Martens, M. Sharma, M.B. Martens, O. Isacson, T. Gasser, J.E. Visser, G. Poelmans (Nijmegen, Netherlands)

12:30pm-2:00pm: Multidisciplinary group program integrating voice and dance movement therapy for Parkinson’s disease patients: Preliminary experience

R. Peled, D. Shpunt, Y. Manor, M. Brozgol, A. Ezra, N. Hezi, R. Hen Simon, J.M. Hausdorff, T. Gurevich (Tel Aviv, Israel)

12:30pm-2:00pm: Neurodegeneration and microgliosis are independent of α-synuclein aggregation in a mouse model of "prion-like" α-synuclein speading

P. Garcia, W. Wemheuer, S. Brioschi, A. Masuch, E. Masliah, V. Koziel, T. Pillot, E. Koncina, C. Jaeger, A. Weihofen, R. Balling, K. Biber, M. Buttini (Esch-sur-Alzette, Luxembourg)

12:30pm-2:00pm: Neuromelanin imaging is useful for monitoring disease progression in Parkinson’s disease and PARK2

T. Hatano, A. Okuzumi, K. Kamagata, K. Daida, D. Taniguchi, M. Hori, H. Yoshino, S. Aoki, N. Hattori (Tokyo, Japan)

12:30pm-2:00pm: Non-motor symptoms profiles in UK white Caucasian and Asian as well as overseas Thai and East Indian patients with Parkinson’s disease

A. Sauerbier, O. Jitkritsadakul, R. Bhidayasiri, H. Kumar, P. Martinez-Martin, R. Banerjee, M. Kulsum, A. Rizos, G. Harington, L. Perkins, T. Chiwera, D. Trivedi, A. Martin, M. Parry, R. Brown, J. Al-Hashel, W. Kamel, A. Kilany, S. Lim, A. Tan, K. Bhattacharyya, R. Walker, K. Ray Chaudhuri, On behalf of EUROPAR, the MDS Non-Motor PD Study Group and the NILS Group (London, United Kingdom)

12:30pm-2:00pm: Objective methods for quantifying the deep brain stimulation (DBS) efficacy in subthalamic-nuclei (STN) neurons with microelectrode recording (MER) technology

V.R. Rama Raju, R.K. Mridula, R. Borgohain, V. Rama Raju (Hyderabad, India)

12:30pm-2:00pm: Olfaction and gray matter volume in Parkinson’s disease. A voxel-based morphometry study

K. Witt, N. Schmidt, O. Granert, L. Paschen, S. Wolff, G. Deuschl (Kiel, Germany)

12:30pm-2:00pm: Opioid K receptor variant delays the onset of dyskinesias in Parkinson’s disease

R. Cilia, R. Asselta, R. Benfante, E. Cereda, D. Vallauri, L. Marabini, D. Fornasari, S. Goldwurm, G. Pezzoli (Milan, Italy)

12:30pm-2:00pm: Optimization of 6-hydroxydopamine animal model of early stage Parkinson´s disease for the assessment of neurorestorative therapies

J.V. Leikas, T.M. Kääriäinen, A.J. Jalkanen, M. Lehtonen, T. Rantamäki, M.M. Forsberg (Kuopio, Finland)

12:30pm-2:00pm: Oral apomorphine film (APL-130277) produces no buccal mucosal irritation: Results of a toxicological study

A. Agro, B. Dzyngel, T. Bilbault, E.J. Pappert (Toronto, ON, Canada)

12:30pm-2:00pm: Parkinson’s disease motor subtypes show similar deficits in inhibitory control

C.M. Tolleson, M. Turchan, N. van Wouwe, S.A. Wylie (Nashville, TN, USA)

12:30pm-2:00pm: Parkinson’s disease onset on non-dominant side predicts greater motor disability

T.A. Finseth, S. Sillau, B. Berman (Aurora, CO, USA)

12:30pm-2:00pm: Pathophysiological mechanisms of bone mass loss for osteoporosis prevalence in Parkinson’s disease

L.A. Leandro, H.A.G. Teive (Curitiba, Brazil)

12:30pm-2:00pm: Pharmacokinetic-pharmacodynamic effects of apomorphine sublingual film (APL-130277) for the rapid management of OFF episodes in patients with Parkinson’s disease

E.J. Pappert, B. Dzyngel, T. Bilbault, A. Agro (Toronto, ON, Canada)

12:30pm-2:00pm: Physical training prevents depressive-like behavior and bdnf decrease in an animal model of Parkinson’s disease

T. Tuon, S.S. Valvasori, J.L. Quevedo, C.T. Souza, R.A. Pinho (Criciúma, Brazil)

12:30pm-2:00pm: PINK1-dependent clearance of depolarized mitochondria is driven by the UPS and can occur independently of (macro)autophagy

A. Rakovic, J. Ziegler, C.U. Mårtensson, J. Prasuhn, K. Shurkewitsch, P. König, H.L. Paulson, C. Klein (Luebeck, Germany)

12:30pm-2:00pm: Piper longum L. alkaloids inhibit lipopolysaccharide-stimulated microglial activation and protect nigral dopaminergic neurons

H. Yang, C. Duan (Beijing, People's Republic of China)

12:30pm-2:00pm: Postural and nonmotor disturbances in Parkinson’s disease

A. Pilipovich, V. Golubev, G. Ptimat (Moscow, Russia)

12:30pm-2:00pm: Pre-formed fibrils injection worsen pathology caused by AAV-mediated over expression of α-synuclein

L.S. Breger, P. Thakur, O.W. Wan, B. Mattsson, K. Luk, V.M. Lee, J. Trojanowski, A. Björklund (Lund, Sweden)

12:30pm-2:00pm: Presynaptic dopamine depletion predicts late complications and time of progression to advanced disease in patients with early Parkinson’s disease

R. Djaldetti, L. Greenbaum, M. Lorberboym (Petah Tiqva, Israel)

12:30pm-2:00pm: Protein levels of SV2A and VGLUT1 in brain tissue from patients with Parkinson’s disease, dementia with Lewy bodies and Alzheimer’s disease

S. Frykman, M. Oosterhof, M.S. Ahmed, D. Howlet, T. Hortobagyi, P. Francis, D. Årsland (Huddinge, Sweden)

12:30pm-2:00pm: Quantifying daily living transitions in patients with Parkinson’s disease using a body-fixed sensor

J.M. Hausdorff, H. Bernad-Elazari, T. Herman, A. Mirelman, E. Gazit, N. Giladi (Tel Aviv, Israel)

12:30pm-2:00pm: Reach-to-grasp impairments of both hands in individuals with Parkinson’s disease

S. Khacharoen, J. Tretriluxana, A. Pisarnpong, P. Chaiyawat (Nakhon Pathom, Thailand)

12:30pm-2:00pm: Relationships of cognitive functions and psychiatric symptoms with motor phenotypes in patients with untreated early-stage Parkinson’s disease

H. Terashi, Y. Ishimura, T. Taguchi, H. Mitoma, H. Aizawa (Tokyo, Japan)

12:30pm-2:00pm: Role of dopamine and GABA during subthalamic and pallidal deep brain stimulation: Evidence of dopamine release during subthalamic Deep Brain Stimulation

A. Nakajima, Y. Shimo, T. Uka, N. Hattori (Tokyo, Japan)

12:30pm-2:00pm: Role of macroautophagy in regulating microglia-mediated neuroinflammation and dopaminergic neuron injury

M. Jin, L. Hu, C. Liu (Suzhou, People's Republic of China)

12:30pm-2:00pm: Saliva swallowing frequency measured using 24-hours ambulatory impedance-pH monitoring in patients with Parkinson’s disease and drooling

J.G. Kalf, S. Scholten, W. Hopman (Nijmegen, Netherlands)

12:30pm-2:00pm: Selenotranscriptomic analyses identify signature selenoproteins in brain regions in a mouse model of Parkinson’s disease

J.Y. Wang, X. Zhang, Y.L. Ye, H.H. Fan, H.M. Wu, W.H. Cheng, J.H. Zhu (Wenzhou, People's Republic of China)

12:30pm-2:00pm: Sodium butyrate attenuates rotenone-induced neurodegeneration via enhancing autophagy and preventing α-synuclein aggregation

L. Liu, C. Han, K. Ma, X. Xu, J. Huang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

12:30pm-2:00pm: Sonographic investigation of Pisa syndrome in Parkinson’s disease

J. Shiraishi, T. Okazaki, M. Mizuba, K. Kajiwara, S. Saeki, R. Matsugaki, T. Takei, T. Uozumi (Fukuoka, Japan)

12:30pm-2:00pm: Speed and severity of toxicity induced by pre-formed α-synuclein fibrils in rat brain is enhanced by α-synuclein overexpression

P. Thakur, L. Breger, B. Mattsson, K. Luk, V.M. Lee, J. Trojanowski, A. Björklund (Lund, Sweden)

12:30pm-2:00pm: Stabilometry characteristics as objective Parkinson’s disease progression biomarkers

I.V. Miliukhina, T.V. Sergeev, E.V. Gracheva, A.V. Kudrevatykh, M.D. Didur (Saint-Petersburg, Russia)

12:30pm-2:00pm: Staging and clinical correlates of cortical thinning in Parkinson’s disease

H. Wilson, F. Niccolini, C. Pellicano, P. Piccini, M. Politis (London, United Kingdom)

12:30pm-2:00pm: Striatal PDE10 expression in Parkinson’s disease (PD) and healthy controls using [¹⁸F]MNI-659 PET imaging

D.S. Russell, D.L. Jennings, O. Barret, G.D. Tamagnan, D. Alagille, J.P. Seibyl, K.L. Marek (New Haven, CT, USA)

12:30pm-2:00pm: Synaptic homeostasis in Parkinson’s disease: An high-density EEG study in different stage of the disease

S. Galati, S. Sarasso, C. Moeller, A. Kalein-Lang, C. Staedler (Lugano, Switzerland)

12:30pm-2:00pm: The contribution of the subthalamic nucleus in gait initiation of subjects with Parkinson’s disease

C. Palmisano, G. Arnulfo, N.G. Pozzi, A. Canessa, A. Leporini, C.A. Frigo, G. Pezzoli, F. Steigerwald, J. Volkmann, I.U. Isaias (Wuerzburg, Germany)

12:30pm-2:00pm: The correlation between N30 SEP and motor function in Parkinson’s disease

S.Y. Kang, Y.J. Kim, Y.H. Sohn, H.I. Ma (Hwaseong, Korea)

12:30pm-2:00pm: The effect of STN-DBS on movement initiation control is modulated by the noradrenergic system: Evidence of an interaction from a combined pharmacological/DBS/EEG study

C. Spay, M. Albares, S. Thobois, E. Broussolle, P. Boulinguez, B. Ballanger (Bron, France)

12:30pm-2:00pm: The effects of viral priming on neurotoxin induced neurodegeneration and synapse dysfunction in cell culture models relevant to Parkinson’s disease

L.K. Olsen, E. Dowd, D. McKernan (Galway, Ireland)

12:30pm-2:00pm: The epigenetic regulation of HIF-1α by SIRT1 in MPP+ treated SH-SY5Y cells

Y. Wu, S. Dong, Y. Guo, Y. Feng, X. Cui, S. Kuo, T. Liu (Shanghai, People's Republic of China)

12:30pm-2:00pm: The kinase Fyn mediates levodopa induced dyskinesias in Parkinson´s disease

J.E. Ferrario, S. Sanz-Blasco, M. Bordone, A. Damianich, A. Bernardi, G. Gomez, I. Taravini, E. Avale, O. Gershanik (Buenos Aires, Argentina)

12:30pm-2:00pm: The small GTP-binding protein Rhes influences midbrain dopaminergic neurons: Behavioral and biochemical studies

A. Pinna, F. Napolitano, G. Costa, P.F. Porceddu, L. Contu, J. Wardas, M.A. Casu, A. Usiello, M. Morelli (Cagliari, Italy)

12:30pm-2:00pm: Toward a new biomarker on Parkinson’s disease: Study of alpha synuclein on upper enteric system by endoscopy

N. Ben Ali, S. Mrabet, S. Hawet, R. Debbiche, S. Belal (Tunis, Tunisia)

12:30pm-2:00pm: Treatment of OFF episodes in Parkinson’s disease: An evaluation of patient and caregiver insights

E.J. Pappert, N. deGruyther, A. Agro (Toronto, ON, Canada)

12:30pm-2:00pm: Treatment of OFF episodes in Parkinson’s disease: An evaluation of physician practices

E.J. Pappert, A. Agro, N. deGruyther (Toronto, ON, Canada)

12:30pm-2:00pm: Urate and homocysteine: Changes in motor and cognitive symptoms in newly diagnosed Parkinson’s disease

I.J. Sleeman, R. Lawson, A. Yarnall, G. Duncan, F. Johnston, T. Khoo, D. Collerton, J.P. Taylor, D. Burn (Newcastle upon Tyne, United Kingdom)

12:30pm-2:00pm: Vagus nerve stimulation as a novel treatment strategy for Parkinson’s disease

A. Farrand, R. Gregory, K. Helke, S. Hays, V. Hinson, H. Boger (Charleston, SC, USA)

12:30pm-2:00pm: Vascular degeneration in Parkinson’s disease

J. Guan, P. Yang, R.L.M. Faill, M. Dragunow, H.J. Waldvogel (Auckland, New Zealand)

12:30pm-2:00pm: Vitamin D in early Parkinson’s disease

I.M. Sleeman, T. Aspray, S. Coleman, G. Duncan, T.K. Khoo, I. Schoenmakers, L. Rochester, D.J. Burn, A.J. Yarnall (Newcastle, United Kingdom)

« View all sessions from the 20th International Congress.